AU2002220979A1 - Intracellular delivery of biological effectors by novel transporter peptide sequences - Google Patents

Intracellular delivery of biological effectors by novel transporter peptide sequences

Info

Publication number
AU2002220979A1
AU2002220979A1 AU2002220979A AU2097902A AU2002220979A1 AU 2002220979 A1 AU2002220979 A1 AU 2002220979A1 AU 2002220979 A AU2002220979 A AU 2002220979A AU 2097902 A AU2097902 A AU 2097902A AU 2002220979 A1 AU2002220979 A1 AU 2002220979A1
Authority
AU
Australia
Prior art keywords
peptide
transporter peptide
effector
transporter
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220979A
Other languages
English (en)
Inventor
Christophe Bonny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xigen SA
Original Assignee
Universite de Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Lausanne filed Critical Universite de Lausanne
Publication of AU2002220979A1 publication Critical patent/AU2002220979A1/en
Assigned to XIGEN SA reassignment XIGEN SA Request for Assignment Assignors: UNIVERSITY OF LAUSANNE
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
AU2002220979A 2000-10-13 2001-10-15 Intracellular delivery of biological effectors by novel transporter peptide sequences Abandoned AU2002220979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24031500P 2000-10-13 2000-10-13
US60/240,315 2000-10-13
PCT/IB2001/002423 WO2002031109A2 (en) 2000-10-13 2001-10-15 Intracellular delivery of biological effectors by novel transporter peptide sequences

Publications (1)

Publication Number Publication Date
AU2002220979A1 true AU2002220979A1 (en) 2002-04-22

Family

ID=22906054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220979A Abandoned AU2002220979A1 (en) 2000-10-13 2001-10-15 Intracellular delivery of biological effectors by novel transporter peptide sequences

Country Status (6)

Country Link
US (3) US7034109B2 (ja)
EP (1) EP1345956A2 (ja)
JP (4) JP4387669B2 (ja)
AU (1) AU2002220979A1 (ja)
CA (1) CA2425610A1 (ja)
WO (1) WO2002031109A2 (ja)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
CA2416757C (en) * 2000-07-21 2011-02-15 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JP4387669B2 (ja) 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
AU2008201592C1 (en) * 2002-06-07 2010-08-12 Xigen Sa Intracellular Delivery of Biological Effectors
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2004073650A2 (en) 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
US7521534B1 (en) * 2003-03-03 2009-04-21 The University Board Of Regents Of Texas System IKK gamma gene products and methods for making and using same
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
CA2535762A1 (en) * 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
AU2005214979B2 (en) 2004-02-17 2009-09-10 The Uab Research Foundation Cytotoxin compound and method of isolation
US8669376B2 (en) * 2004-02-17 2014-03-11 University Of South Florida Cytotoxin compounds and methods of isolation
BR122019004903B1 (pt) 2004-07-27 2021-11-03 The Regents Of The University Of California Célula hospedeira de saccharomyces cerevisiae geneticamente modificada, composição compreendendo a mesma e método para aumentar a produção de amorfa-4,11-dieno através da via do mevalonato na célula hospedeira
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2007047623A2 (en) * 2005-10-14 2007-04-26 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
CA2638915A1 (en) * 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
AU2007272906B2 (en) * 2006-07-12 2013-01-31 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US7935092B1 (en) 2006-07-25 2011-05-03 Twin Star Medical, Inc. Self-introducing injection and aspiration device
WO2008022015A2 (en) * 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
CU23630A1 (es) * 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
ES2951646T3 (es) * 2008-02-21 2023-10-24 Burnham Institute For Medical Res Métodos y composiciones relacionados con péptidos y proteínas con elementos C-terminales
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010005534A2 (en) * 2008-06-30 2010-01-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome inhibitors for selectively inducing apoptosis in cancer cells
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
ES2334315B1 (es) * 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
RU2011108560A (ru) 2008-08-05 2012-09-10 Юниверсити Оф Саут Флорида (Us) Способы лечения когнитивного нарушения
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
US9221808B2 (en) 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013112722A1 (en) 2012-01-24 2013-08-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of rho associated protein kinases (rock) and methods of use
JP6233812B2 (ja) 2012-03-07 2017-11-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 選択的ヒストンデアセチラーゼ６阻害剤
JP2015529073A (ja) 2012-08-20 2015-10-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物可逆性基を有するポリヌクレオチド
US10098967B2 (en) 2012-12-03 2018-10-16 Ohio State Innovation Foundation Self-assembly of therapeutic agent-peptide nanostructures
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
CN105592850B (zh) 2013-08-06 2019-11-15 H·李·莫菲特癌症中心研究所公司 Ack1/tnk2酪氨酸激酶的抑制剂
US10626178B2 (en) 2013-08-21 2020-04-21 Raz Yirmiya Treatment of mood and stress related disorders
WO2015025323A1 (en) 2013-08-21 2015-02-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mood and stress related disorders
AU2015209143A1 (en) 2014-01-23 2016-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin derivatives
WO2015112904A1 (en) 2014-01-24 2015-07-30 University Of Florida Research Foundation, Inc. Socs mimetics for the treatment of diseases
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
WO2015153560A1 (en) 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CA2949705A1 (en) 2014-05-21 2015-11-26 Cycloporters, Inc. Cell penetrating peptides and methods of making and using thereof
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016154586A1 (en) 2015-03-26 2016-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Toll-like receptor 2 ligands and methods of making and using thereof
EP3294316A4 (en) 2015-05-06 2018-10-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target mc1r
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016197067A1 (en) 2015-06-05 2016-12-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gm-csf/cd40l vaccine and checkpoint inhibitor combination therapy
WO2017023899A1 (en) 2015-08-02 2017-02-09 H. Lee Moffitt Cancer Center & Research Institute Inhibitors of ack1/tnk2 tyrosine kinase
EP3350196A4 (en) 2015-09-17 2019-04-03 Ohio State Innovation Foundation CARBORAN COMPOUNDS AND METHODS OF USE
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
JP2018536426A (ja) 2015-12-09 2018-12-13 ヴァンダービルト ユニヴァーシティ ミクロモノスポラ・カルボナセア変種アウランティアカ（Ｍｉｃｒｏｍｏｎｏｓｐｏｒａ ｃａｒｂｏｎａｃｅａ ｖａｒ ａｕｒａｎｔｉａｃａ）におけるエベルニノマイシンアナログの生合成
WO2017136534A1 (en) 2016-02-03 2017-08-10 Kennesaw State University Researcha And Service Foundation, Inc. Signal molecules as cell penetration agents
WO2017155929A1 (en) * 2016-03-10 2017-09-14 The University Of Toledo Targeting of human glucocorticoid receptor beta in cancer
US11203576B2 (en) 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
KR102520814B1 (ko) 2016-03-16 2023-04-11 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 작동자 t 세포 기능 개선을 위한 세레브론에 대한 소분자
AU2017260460A1 (en) 2016-05-04 2018-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. A delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer
AU2017312116A1 (en) 2016-08-17 2019-03-07 Solstice Biologics, Ltd. Polynucleotide constructs
CA3043464A1 (en) 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US11583525B2 (en) 2017-06-06 2023-02-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Geranylgeranyltransferase I inhibitor for treatment of a PTEN defective cancer
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
JP2021501201A (ja) 2017-10-27 2021-01-14 オハイオ ステート イノベーション ファウンデーション ステープルペプチドの細胞内送達のためのポリペプチド接合体
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3787671A4 (en) 2018-05-04 2022-06-15 Ohio State Innovation Foundation NON-PEPTIDE CELL-PENETRATING MOTIFS
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
US20210246185A1 (en) * 2018-06-04 2021-08-12 Howard Hughes Medical Institute Inverted transporter polypeptides and methods of using
CN112512589A (zh) 2018-07-11 2021-03-16 H·李·莫菲特癌症中心研究有限公司 二聚体免疫调节化合物对抗基于cereblon的机制
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
WO2020028814A1 (en) 2018-08-03 2020-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of wee1 kinase
IL307298A (en) 2021-03-31 2023-11-01 Entrada Therapeutics Inc Cell-penetrating circular peptides
AU2022271873A1 (en) 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
WO2022240721A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
EP4337261A2 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating mrna splicing
EP4359006A1 (en) 2021-06-23 2024-05-01 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
AU2022339769A1 (en) 2021-09-01 2024-03-28 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
WO2023219933A1 (en) 2022-05-09 2023-11-16 Entrada Therapeutics, Inc. Compositions and methods for delivery of nucleic acid therapeutics
WO2024015924A2 (en) 2022-07-15 2024-01-18 Entrada Therapeutics, Inc. Hybrid oligonucleotides
WO2024073042A1 (en) 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
JPH0466595A (ja) * 1990-07-02 1992-03-02 General Hospital Corp 哺乳動物ｇａｐ―４３組成物および使用方法
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
US5994108A (en) * 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
CA2131620A1 (en) * 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
WO1994004562A1 (en) * 1992-08-13 1994-03-03 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
US5545551A (en) * 1992-08-28 1996-08-13 Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of pur protein
WO1994023751A1 (de) 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5989814A (en) * 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
JP4129298B2 (ja) 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6270956B1 (en) * 1997-12-11 2001-08-07 The Salk Institute For Biological Studies Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor
ATE258946T1 (de) 1998-08-28 2004-02-15 Gryphon Sciences Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
EP1210362A2 (en) * 1999-09-01 2002-06-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
JP4387669B2 (ja) * 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達

Also Published As

Publication number Publication date
JP2009195253A (ja) 2009-09-03
JP2009005694A (ja) 2009-01-15
JP2004511494A (ja) 2004-04-15
US20060205665A1 (en) 2006-09-14
EP1345956A2 (en) 2003-09-24
JP4388107B2 (ja) 2009-12-24
US7034109B2 (en) 2006-04-25
US20020120100A1 (en) 2002-08-29
US6960648B2 (en) 2005-11-01
WO2002031109A2 (en) 2002-04-18
CA2425610A1 (en) 2002-04-18
US20040110690A1 (en) 2004-06-10
US7538091B2 (en) 2009-05-26
WO2002031109A3 (en) 2003-01-16
JP2007330265A (ja) 2007-12-27
JP4387669B2 (ja) 2009-12-16

Similar Documents

Publication Publication Date Title
US6960648B2 (en) Intracellular delivery of biological effectors
US7033597B2 (en) Intracellular delivery of biological effectors
CN106715462B (zh) α4β7整联蛋白硫醚肽拮抗剂
JP6499157B2 (ja) 新規のα４β７ペプチド二量体アンタゴニスト
JP2016515620A (ja) 新規のα４β７ペプチド拮抗薬
JP2013513382A (ja) 細胞内ターゲット結合用二座ペプチドバインダー
Parthasarathy et al. The medicinal chemistry of therapeutic peptides: Recent developments in synthesis and design optimizations
CZ20013318A3 (cs) Noví LH-RH-antagonisté se zlepąenými vlastnostmi rozpustnosti
Park et al. The use of one-bead one-compound combinatorial library method to identify peptide ligands for α4β1 integrin receptor in non-Hodgkin's lymphoma
WO2015055148A1 (zh) Yap蛋白抑制多肽及其应用
AU2001249789B2 (en) Binding peptides for carcinoembryonic antigen (cea)
JP3805679B2 (ja) 新規のｌｈｒｈ拮抗物質、その製造および医薬としてのその使用
AU2008201592B2 (en) Intracellular Delivery of Biological Effectors
AU2007216926A1 (en) Intracellular Delivery of Biological Effectors by Novel Transporter Peptide Sequences
Roberts et al. Kappa agonist CovX-bodies
Chavatte et al. Rhenium (Re) and technetium (Tc)‐99M oxocomplexes of neurotensin (8‐13)
Einsiedel et al. Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors
Klimentzou et al. Solid‐phase Synthesis of a Peptide Derivative of Thymosin alpha1 and Initial Studies on its 99mTc‐Radiolabelling
Hamza et al. Synthesis of Some Analogues of Polymyxin E1 Antibiotic Using Automated Solid Phase Peptide Synthesis Assisted With Microwave Irradiation
WO1999045020A1 (en) Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
Chen et al. Chemobodies as Targeting Moieties of Insulin-Secreting Cells
Lian Development and Optimization of Protein-Protein Interaction Inhibitors by Combinatorial and Medicinal Chemistry
JPH1171397A (ja) 新規生理活性ペプチド

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted